SCHEMBL7125553

SCHEMBL7125553

Clc1ncnc2c1CCc1sccc1-2

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AXL P30530 1/20 0.40
MKNK1 Q9BUB5 1/20 0.40
MKNK2 Q9HBH9 1/20 0.40
NOS2 P35228 1/20 0.35
DYRK1A Q13627 2/20 0.35
PLK4 O00444 1/20 0.35
CHEK1 O14757 1/20 0.35
AURKA O14965 1/20 0.35
DAPK3 O43293 1/20 0.35
PRKD3 O94806 1/20 0.35
MAP4K4 O95819 1/20 0.35
PAK4 O96013 1/20 0.35
PIM1 P11309 1/20 0.35
PDGFRA P16234 1/20 0.35
PRKACA P17612 1/20 0.35
LTK P29376 1/20 0.35
GRK5 P34947 1/20 0.35
KDR P35968 1/20 0.35
MAP2K2 P36507 1/20 0.35
FLT3 P36888 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29558555 1.00 AXL (0.40) AXLMKNK1MKNK2NOS2DYRK1A
SCHEMBL7130459 0.75 AXL (0.39) AXLMKNK1MKNK2NOS2DYRK1A
SCHEMBL28725425 0.73
SCHEMBL7130469 0.71 DYRK1A (0.66) DYRK1A
SCHEMBL7130556 0.67 DYRK1A (0.41) DYRK1ACDK9MAPTSMN1; SMN2KIT
SCHEMBL9837155 0.66 DYRK1A (0.54) DYRK1ASMN1; SMN2
SCHEMBL9778029 0.64 HTR2A (0.39) KDRADRA2AADRA2BMAPTKMT2A
SCHEMBL7576114 0.61 NOS2 (0.39) NOS2DYRK1APLK4CHEK1AURKA
SCHEMBL4041500 0.61 GRM4 (0.39) DYRK1APLK4CHEK1AURKADAPK3
SCHEMBL2708066 0.60 DRD4 (0.51) NOS2DYRK1APLK4CHEK1AURKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114380841-A Tricyclic or dihydroquinazoline compounds as AKT inhibitors 南京正大天晴制药有限公司 2022-04-22 CN disclosed
US-20030176454-A1 N-coating heterocyclic compounds FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-09-18 US disclosed
WO-2001087845-A2 N-CONTAINING HETEROCYCLIC COMPOUNDS AND THEIR USE AS 5-HT ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2001-11-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030176454-A1 N-coating heterocyclic compounds H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, GNE, NIT2 AXL 529/4885MKNK1 2608/4885MKNK2 2124/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.